nach oben

Tumor Biology

Erschienen in:

01.09.2014 | Research Article

Significance of estrogen receptor subtypes in breast tumorigenesis and progression

verfasst von: Weiliang Sun, Chijiang Gu, Minming Xia, Guoping Zhong, Haojun Song, Junming Guo

Erschienen in: Tumor Biology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to investigate the effects of estrogen receptor (ER) subtypes (ERα and ERβ) on breast cancer development and progression. The expression level of ERα and ERβ in breast cancer tissues and paired normal breast tissues were detected by Western blot analysis and immunohistochemistry (IHC) staining. The features of ERα and ERβ status in cancer tissues or normal breast tissues and the correlations between clinicopathological characteristics and prognosis were analyzed. The expression levels of ERα and ERβ in breast cancer tissues are significantly lower than those in the paired normal tissues. The expression of ERβ is decreased more than that of ERα. ERα expression levels in cancer tissues are associated with tumor diameter, tumor–node–metastasis (TNM) stage, and progesterone receptor (PR) status. However, ERβ expression levels in cancer tissues are not correlated with clinicopathological factors of patients with breast cancer. In conclusion, ER subtypes might play different roles in the development of breast cancer.

Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905–31.CrossRefPubMed

Paris O, Ferraro L, Grober OMV, Ravo M, De Filippo MR, Giurato G, et al. Direct regulation of microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer. Oncogene. 2012;31(38):4196–206.CrossRefPubMed

Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004;10:7490–9.CrossRefPubMed

Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH. Relationship of coregulator and estrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer. 2002;87:1411–6.PubMedCentralCrossRefPubMed

Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001;7:4338s–42s. discussion 4411s—4412s.PubMed

Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010;16:2702–8.PubMedCentralCrossRefPubMed

Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology. 2006;147:4831–42.CrossRefPubMed

Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005;24:6605–16.CrossRefPubMed

Cato AC, Nestl A, Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Science STKE. 2002;138:re9.

10.

Nemere I, Pietras RJ, Blackmore PF. Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem. 2003;88:438–45.CrossRefPubMed

11.

Ordonez-Moran P, Munoz A. Nuclear receptors: genomic and nongenomic effects converge. Cell Cycle. 2009;8:1675–80.CrossRefPubMed

12.

Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 1997;277:1508–10.CrossRefPubMed

13.

Salvatori L, Pallante P, Ravenna L, Chinzari P, Frati L, Russo MA, et al. Estrogens and selective estrogen receptor (ER) modulators regulate EGF receptor gene expression through human ERα and β subtypes via an Sp1 site. Oncogene. 2003;22:4875–81.CrossRefPubMed

14.

Safe S, Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Nucleic Acid Res Mol Biol. 2004;77:1–36.CrossRef

15.

Panno ML, Mauro L, Marsico S, Bellizzi D, Rizza P, Morelli C, et al. Evidence that mouse IRS-1 belongs to the family gene which promoter is activated by ERα through its interaction with Sp-1. J Mol Endocrinol. 2006;36:91–105.CrossRefPubMed

16.

Mauro L, Catalano S, Bossi G, Pellegrino M, Barone I, Morales S, et al. Evidence that leptin upregulates E-cadherin expression in breast cancer effects on tumor growth and progression. Cancer Res. 2007;67:3412–21.CrossRefPubMed

17.

Higgins KJ, Shengxi L, Abdelrahim M, Vanderlaag K, Liu X, Porter W, et al. Vascular endothelial growth factor receptor-2 expression is down-regulated by 17 beta estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp-1 proteins. Mol Endocrinol. 2008;22:388–402.PubMedCentralCrossRefPubMed

18.

Varlakhanova N, Snyder C, Jose S, Hahm JB, Privalsky ML. Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. Mol Cell Biol. 2010;30:1434–45.PubMedCentralCrossRefPubMed

19.

Cheng L, Li J, Han Y, Lin J, Niu C, Zhou Z, et al. PES1 promotes breast cancer by differentially regulating ERα and ERβ. J Clin Invest. 2012;122:2857–70.PubMedCentralCrossRefPubMed

20.

Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res. 1998;58:3197–201.PubMed

21.

Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade and proliferation rate in breast cancer. Am J Pathol. 2000;156:29–35.PubMedCentralCrossRefPubMed

Titel: Significance of estrogen receptor subtypes in breast tumorigenesis and progression
verfasst von: Weiliang Sun
Chijiang Gu
Minming Xia
Guoping Zhong
Haojun Song
Junming Guo
Publikationsdatum: 01.09.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 9/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2152-1

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Significance of estrogen receptor subtypes in breast tumorigenesis and progression

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Establishment and analysis of osteosarcoma cell sublines with different metastatic characteristics

Influence of interleukin-28B polymorphism on progression to hepatitis virus-induced hepatocellular carcinoma

Erratum to: Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis

TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK-3β pathway

Loss of SNAIL inhibits cellular growth and metabolism through the miR-128-mediated RPS6KB1/HIF-1α/PKM2 signaling pathway in prostate cancer cells

Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie